HeraMED Director Converts Performance Rights Into Ordinary Shares

HeraMED Ltd. ( (AU:HMD) ) has issued an announcement.

HeraMED Ltd. has disclosed a change in director Anoushka Gungadin’s interests following the vesting and exercise of performance rights into ordinary shares. The update reflects a routine equity conversion that alters the mix of her holdings without any cash consideration.

Gungadin converted 2,633,860 vested performance rights into the same number of fully paid ordinary shares, reducing her remaining performance rights to 13,166,140. Her portfolio now comprises ordinary shares, unlisted options with varying exercise prices and expiries, and a reduced but still substantial tranche of performance rights, signaling continued equity-based alignment with shareholder interests.

The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.

More about HeraMED Ltd.

HeraMED Ltd. is an Australian-listed company, though this filing offers no additional details on its industry, products, or services. The announcement focuses solely on changes in a director’s holdings rather than operational or strategic aspects of the business.

YTD Price Performance: 22.22%

Average Trading Volume: 750,443

Technical Sentiment Signal: Buy

Current Market Cap: A$49.12M

For detailed information about HMD stock, go to TipRanks’ Stock Analysis page.